Out of ‘Stealth’ Mode, QurAlis Expects First QRL-201 Trial in 2022

Out of ‘Stealth’ Mode, QurAlis Expects First QRL-201 Trial in 2022

306532

Out of ‘Stealth’ Mode, QurAlis Expects First QRL-201 Trial in 2022

QurAlis is advancing the development of QRL-201, its “groundbreaking” lead treatment candidate for amyotrophic lateral sclerosis (ALS), and expects to initiate its first clinical trial in late 2022. The stem cell technology company said it is now conducting formal preclinical studies to assess QRL-201’s therapeutic potential, and expects to use the data it collects to support the future launch of first-in-human trials. “We are excited to bring QRL-201 out of stealth and continue advancing our…

You must be logged in to read/download the full post.